General Announcement::Top Line Results from Phase 3 Safety Study Evaluating Ryaltris

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
14-Dec-2017 12:49:58
Status
New
Announcement Sub Title
Top Line Results from Phase 3 Safety Study Evaluating Ryaltris
Announcement Reference
SG171214OTHR8KQH
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
14/12/2017 10:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals Announces Top-Line Results from a Phase 3 Safety Study Evaluating Ryaltris in Patients with Perennial Allergic Rhinitis

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Request you to kindly take the same on record.

Attachments

PR1412UP.pdf
Total size =1005K